Table 1.
Characteristics of studies included in meta-analysis.
| Author (year) | Study design | Study location | OVDs | N (eyes) | Mean age | Age (SD) |
|---|---|---|---|---|---|---|
| Arshinoff (1997) [11] | RCT | Canada | MicroVisc | 51 | 70 | 10 |
| RCT | Canada | Healon | 49 | 70 | 11 | |
|
| ||||||
| Arshinoff (1998) [4] | RCT | Canada | MicroVisc Plus | 100 | 70 | 10 |
| RCT | Canada | Healon GV | 100 | 66 | 10 | |
|
| ||||||
| Arshinoff (2002) [3] | RCT | Canada | Healon5 | 50 | 71.5 | 9.6 |
| RCT | Canada | Healon GV | 99 | 71.7 | 9.6 | |
| RCT | Canada | Healon | 49 | 71.9 | 7.5 | |
|
| ||||||
| Auffarth (2017) [18] | RCT | Europe | Twinvisc | 109 | 71.9 | 7.4 |
| RCT | Europe | DuoVisc | 111 | 72.5 | 7.9 | |
|
| ||||||
| Behndig (2002) [19] | RCT | Sweden | Healon GV | 21 | 72 | 10.4 |
| RCT | Sweden | Viscoat + Healon GV | 20 | 72.8 | 11.7 | |
| RCT | Sweden | Viscoat + Provisc | 21 | 76.5 | 8.4 | |
|
| ||||||
| Chiselita (2008) [20] | RCT | Romania | Viscoat | 44 | 68.8 | 9.8 |
| RCT | Romania | Provisc | 52 | 68.8 | 9.8 | |
|
| ||||||
| Davis (2000) [2] | RCT | USA | Amvisc Plus | 17 | — | — |
| RCT | USA | OcuCoat | 17 | — | — | |
| RCT | USA | Viscoat | 16 | — | — | |
|
| ||||||
| Embriano (1989) [21] | RCT | USA | Sodium chondroitin sulfate-NaHa | 50 | — | — |
| RCT | USA | NaHa | 50 | — | — | |
|
| ||||||
| Espindola (2012) [22] | RCT | Brazil | DisCoVisc | 39 | 71.5 | 7.9 |
| RCT | Brazil | 2% HPMC | 39 | 71.5 | 7.9 | |
|
| ||||||
| Holzer (2001) [1] | RCT | Germany | Healon GV | 12 | 71.2 | 7.8 |
| RCT | Germany | Healon5 | 19 | 71.2 | 7.8 | |
| RCT | Germany | Viscoat | 20 | 71.2 | 7.8 | |
| RCT | Germany | OcuCoat | 15 | 71.2 | 7.8 | |
| RCT | Germany | Celoftal | 15 | 71.2 | 7.8 | |
|
| ||||||
| Hutz (1996) [23] | RCT | Germany | Methocel | 50 | — | — |
| RCT | Germany | Viscoat | 50 | — | — | |
| RCT | Germany | Healon | 50 | — | — | |
| RCT | Germany | Healon GV | 50 | — | — | |
|
| ||||||
| Kim (2004) [24] | RCT | Korea | Soft Shell (Viscoat + Hyal-2000) | 69 | 64.15 | 12.92 |
| RCT | Korea | Viscoat | 64 | 67.53 | 10.19 | |
| RCT | Korea | Hyal-2000 | 64 | 63.22 | 11.51 | |
| RCT | Korea | Provisc | 55 | 63.3 | 12.78 | |
|
| ||||||
| Kocak-Altintas (2006) [25] | RCT | Turkey | BD Visc | 83 | 65.6 | 11.1 |
| RCT | Turkey | Healon | 83 | 65.8 | 11.3 | |
|
| ||||||
| Kohnen (1996) [12] | RCT | Germany | Healon | 30 | 73.2 | 9.2 |
| RCT | Germany | Healon GV | 30 | 73.2 | 9.2 | |
|
| ||||||
| Lee (2011) [26] | RCT | Korea | Amvisc Plus | 31 | 65.42 | 12.20 |
| RCT | Korea | Balanced salt solution + Amvisc Plus | 31 | 63.23 | 9.44 | |
|
| ||||||
| Miller (1999) [5] | RCT | USA | Healon GV | 70 | 75.8 | 6.79 |
| RCT | USA | Viscoat | 70 | 75.5 | 6.38 | |
|
| ||||||
| Miyata (2002a) [27] | RCT | Japan | Opegan | 50 | 75.6 | 8.0 |
| RCT | Japan | Healon | 28 | 74.3 | 8.7 | |
|
| ||||||
| Miyata (2002b) [28] | RCT | Japan | Soft Shell | 37 | 74.8 | 10.2 |
| RCT | Japan | Healon | 23 | 76.5 | 8.5 | |
|
| ||||||
| Moschos (2011) [13] | RCT | Greece | Viscoat | 41 | 77.6 | 8.4 |
| RCT | Greece | Visthesia | 36 | 77.7 | 8.7 | |
|
| ||||||
| Neumayer (2008) [29] | RCT | UK | Neocrom Cohesive | 29 | 75 | — |
| RCT | UK | Healon | 29 | 75 | — | |
|
| ||||||
| Oshika (2004) [30] | RCT | Japan | Healon5 | 79 | 69 | 10 |
| RCT | Japan | Healon | 78 | 71 | 9 | |
|
| ||||||
| Oshika (2010) [6] | RCT | Japan | DisCoVisc | 157 | 70.3 | 8.2 |
| RCT | Japan | Healon5 | 166 | 70.3 | 7.9 | |
|
| ||||||
| Ray-Chaudhary (2005) [31] | RCT | UK | Ophthalin | 51 | — | — |
| RCT | UK | HPMC-Ophtal | 50 | — | — | |
|
| ||||||
| Rainer (2000) [7] | RCT | Austria | Healon5 | 35 | 75.5 | 9.1 |
| RCT | Austria | Viscoat | 35 | 75.5 | 9.1 | |
|
| ||||||
| Rainer (2001) [8] | RCT | Austria | OcuCoat | 40 | 75.9 | 9.3 |
| RCT | Austria | Viscoat | 40 | 75.9 | 9.3 | |
|
| ||||||
| Rainer (2007) [10] | RCT | Austria | NaHa 1% | 40 | 75.1 | 8.0 |
| RCT | Austria | 2% HPMC | 40 | 75.1 | 8.0 | |
|
| ||||||
| Rainer (2008) [32] | RCT | Austria | Viscoat | 30 | 76.6 | 7.4 |
| RCT | Austria | DuoVisc | 30 | 76.6 | 7.4 | |
|
| ||||||
| Ravalico (1997) [33] | RCT | Italy | Healon | 16 | 64.06 | 5.97 |
| RCT | Italy | Healon GV | 15 | 61.64 | 9.56 | |
| RCT | Italy | Viscoat | 14 | 62.67 | 6.34 | |
| RCT | Italy | Hymecel | 13 | 62.85 | 7.55 | |
|
| ||||||
| Schwenn (2000) [34] | RCT | Germany | Healon5 | 20 | — | — |
| RCT | Germany | Viscoat | 28 | — | — | |
|
| ||||||
| Stankovic (2008) [35] | RCT | Serbia | 2% HPMC | 20 | — | — |
| RCT | Serbia | Chondroitin sulfate 4%- NaHa 3% | 20 | — | — | |
|
| ||||||
| Storr-Paulsen (2007) [36] | RCT | Denmark | Celoftal | 17 | 77.9 | 8.1 |
| RCT | Denmark | Vitrax | 16 | 76.6 | 10.4 | |
| RCT | Denmark | Healon | 19 | 76.4 | 13.1 | |
|
| ||||||
| Strobel (1997) [37] | RCT | Germany | Healon GV | 30 | 68.9 | 10.8 |
| RCT | Germany | Healon | 30 | 73.6 | 10.2 | |
|
| ||||||
| Thirumalai (2007) [38] | RCT | UK | Healon GV | 415 | — | — |
|
| ||||||
| Vajpayee (2005) [39] | RCT | India | Viscoat | 19 | 69.6 | 9.2 |
| RCT | India | Healon GV | 19 | 65.8 | 7.8 | |
| RCT | India | Healon5 | 18 | 70.8 | 9.9 | |
|
| ||||||
| Yachimori (2004) [40] | RCT | Japan | Opegan | 34 | 68.6 | 8.2 |
| RCT | Japan | Soft Shell | 35 | 70.7 | 8.3 | |